Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charles M Alexander

Showing results (11-20 of 43) with videos related to

Pageof 5
Sort By:
Current Opinion in Lipidology|November 11, 2006
Reassessment of cardiovascular risk in diabetesJonathan R Jaffe, Soma S Nag, Pamela B Landsman, et al.
Journal of Diabetes Science and Technology|January 5, 2010
Treatment with sitagliptin or metformin does not increase body weight despite predicted reductions in urinary glucose excretionSteven B Waters, Brian G Topp, Scott Q Siler, et al.
Diabetes|April 30, 2003
NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and olderCharles M Alexander, Pamela B Landsman, Steven M Teutsch, et al.
BMC Endocrine Disorders|March 9, 2012
Factors associated with initiation of antihyperglycaemic medication in UK patients with newly diagnosed type 2 diabetesAlan J Sinclair, Charles M Alexander, Michael J Davies, et al.
The Journal of Cardiovascular Nursing|January 6, 2005
The Hyperlipidemia: Attitudes and Beliefs in Treatment (HABIT) survey for patients: results of a validation studyKathleen A Foley, Joseph Vasey, Kathleen Berra, et al.
The American Journal of Medicine|August 2, 2003
Evaluating the benefits of treating dyslipidemia: the importance of diabetes as a risk factorSteven A Grover, Louis Coupal, Hanna Zowall, et al.
The American Journal of Cardiology|January 13, 2004
Population implications of changes in lipid management in patients with coronary heart diseaseKathleen A Foley, Mark W Massing, Ross J Simpson, et al.
Diabetes Care|April 28, 2005
Glycemic control continues to deteriorate after sulfonylureas are added to metformin among patients with type 2 diabetesMichael N Cook, Cynthia J Girman, Peter P Stein, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|March 16, 2007
Contemporary analysis of secondary failure of successful sulfonylurea therapyGregory A Nichols, Charles M Alexander, Cynthia J Girman, et al.
Diabetes Spectrum : a Publication of the American Diabetes Association|February 25, 2021
Comparison of Protocols to Reduce Diabetic Ketoacidosis in Patients With Type 1 Diabetes Prescribed a Sodium-Glucose Cotransporter 2 InhibitorRhea Teng, Martin Kurian, Kelly L Close, et al.
Pageof 5

Showing results (11-20 of 43) with videos related to

Sort By:
Pageof 5
Current Opinion in Lipidology|November 11, 2006
Reassessment of cardiovascular risk in diabetesJonathan R Jaffe, Soma S Nag, Pamela B Landsman, et al.
Journal of Diabetes Science and Technology|January 5, 2010
Treatment with sitagliptin or metformin does not increase body weight despite predicted reductions in urinary glucose excretionSteven B Waters, Brian G Topp, Scott Q Siler, et al.
Diabetes|April 30, 2003
NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and olderCharles M Alexander, Pamela B Landsman, Steven M Teutsch, et al.
BMC Endocrine Disorders|March 9, 2012
Factors associated with initiation of antihyperglycaemic medication in UK patients with newly diagnosed type 2 diabetesAlan J Sinclair, Charles M Alexander, Michael J Davies, et al.
The Journal of Cardiovascular Nursing|January 6, 2005
The Hyperlipidemia: Attitudes and Beliefs in Treatment (HABIT) survey for patients: results of a validation studyKathleen A Foley, Joseph Vasey, Kathleen Berra, et al.
The American Journal of Medicine|August 2, 2003
Evaluating the benefits of treating dyslipidemia: the importance of diabetes as a risk factorSteven A Grover, Louis Coupal, Hanna Zowall, et al.
The American Journal of Cardiology|January 13, 2004
Population implications of changes in lipid management in patients with coronary heart diseaseKathleen A Foley, Mark W Massing, Ross J Simpson, et al.
Diabetes Care|April 28, 2005
Glycemic control continues to deteriorate after sulfonylureas are added to metformin among patients with type 2 diabetesMichael N Cook, Cynthia J Girman, Peter P Stein, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|March 16, 2007
Contemporary analysis of secondary failure of successful sulfonylurea therapyGregory A Nichols, Charles M Alexander, Cynthia J Girman, et al.
Diabetes Spectrum : a Publication of the American Diabetes Association|February 25, 2021
Comparison of Protocols to Reduce Diabetic Ketoacidosis in Patients With Type 1 Diabetes Prescribed a Sodium-Glucose Cotransporter 2 InhibitorRhea Teng, Martin Kurian, Kelly L Close, et al.
Pageof 5